"A Time to Tear Down and a Time to Mend": The Role of Eicosanoids in Atherosclerosis

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2024 Oct 23

PMID 39441911

Authors

Samuel C R Sherratt

R Preston Mason

Peter Libby

Deepak L Bhatt

Affiliations

Soon will be listed here.

References

Climax J, Newsome P, Hamza M, Weissbach M, Coughlan D, Sattar N . Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. J Am Heart Assoc. 2020; 9(16):e016334. PMC: 7660824. DOI: 10.1161/JAHA.119.016334. View

Gabbs M, Leng S, Devassy J, Monirujjaman M, Aukema H . Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. Adv Nutr. 2015; 6(5):513-40. PMC: 4561827. DOI: 10.3945/an.114.007732. View

Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M . Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol. 2013; 113(3):441-5. DOI: 10.1016/j.amjcard.2013.10.011. View

Sherratt S, Juliano R, Mason R . Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochim Biophys Acta Biomembr. 2020; 1862(7):183254. DOI: 10.1016/j.bbamem.2020.183254. View

Schebb N, Kuhn H, Kahnt A, Rund K, ODonnell V, Flamand N . Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?. Front Pharmacol. 2022; 13:838782. PMC: 8924552. DOI: 10.3389/fphar.2022.838782. View

Sato T, Horikawa M, Takei S, Yamazaki F, Ito T, Kondo T . Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques. Arterioscler Thromb Vasc Biol. 2019; 39(9):1802-1816. DOI: 10.1161/ATVBAHA.119.313093. View

Wada M, DeLong C, Hong Y, Rieke C, Song I, Sidhu R . Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem. 2007; 282(31):22254-66. DOI: 10.1074/jbc.M703169200. View

Libby P . The changing landscape of atherosclerosis. Nature. 2021; 592(7855):524-533. DOI: 10.1038/s41586-021-03392-8. View

Fredman G, Hellmann J, Proto J, Kuriakose G, Colas R, Dorweiler B . An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun. 2016; 7:12859. PMC: 5036151. DOI: 10.1038/ncomms12859. View

10.

Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, Hamilton J . Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis. Arterioscler Thromb Vasc Biol. 2015; 35(5):1123-33. PMC: 4415167. DOI: 10.1161/ATVBAHA.115.305324. View

11.

Bhatt D, Steg P, Miller M, Brinton E, Jacobson T, Ketchum S . Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2018; 380(1):11-22. DOI: 10.1056/NEJMoa1812792. View

12.

Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y . Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2010; 18(2):99-107. DOI: 10.5551/jat.5876. View

13.

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

14.

Simopoulos A . An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. 2016; 8(3):128. PMC: 4808858. DOI: 10.3390/nu8030128. View

15.

Markworth J, Kaur G, Miller E, Larsen A, Sinclair A, Maddipati K . Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid. FASEB J. 2016; 30(11):3714-3725. PMC: 5067251. DOI: 10.1096/fj.201600360R. View

16.

Aung T, Halsey J, Kromhout D, Gerstein H, Marchioli R, Tavazzi L . Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018; 3(3):225-234. PMC: 5885893. DOI: 10.1001/jamacardio.2017.5205. View

17.

Dalli J, Gomez E . Reply to: Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples. Nat Commun. 2023; 14(1):7293. PMC: 10638266. DOI: 10.1038/s41467-023-41767-9. View

18.

Sherratt S, Libby P, Dawoud H, Bhatt D, Mason R . Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. J Am Heart Assoc. 2024; 13(14):e034076. PMC: 11292741. DOI: 10.1161/JAHA.123.034076. View

19.

ODonnell V, Schebb N, Milne G, Murphy M, Thomas C, Steinhilber D . Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples. Nat Commun. 2023; 14(1):7172. PMC: 10636151. DOI: 10.1038/s41467-023-41766-w. View

20.

Sherratt S, Mason R, Libby P, Steg P, Bhatt D . Do patients benefit from omega-3 fatty acids?. Cardiovasc Res. 2024; 119(18):2884-2901. PMC: 10874279. DOI: 10.1093/cvr/cvad188. View